Century Therapeutics FY2024 net loss $126.6M; discontinues ELiPSE-1, focuses on CNTY-308

Century Therapeutics, Inc.

Net loss $126.6M for FY2024 ($136.7M in 2023); cash $220.1M, runway into Q4 2026.
Discontinued ELiPSE-1 Phase 1 trial for CNTY-101 in R/R NHL; data not transformational.
Pipeline re-prioritized to four programs led by CNTY-308 (CD19 CAR-iT); IND-enabling studies mid-2025.
First patient dosed in CALiPSO-1 Phase 1 trial for CNTY-101 in autoimmunity; CARAMEL IIT to start mid-2025.
Collaboration revenue from BMS $6.6M; R&D expenses $107.2M (up from $92.7M) driven by trial and manufacturing costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.